Dilip R. Karnad

Dilip R. Karnad

Auto-generated profile, based on publicly available information

Dilip R. Karnad

Jupiter Hosp, Dept Crit Care, Thana, Maharashtra, India

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Chest
Verified
Journal Article
Closed access
PDF file
TPTanmay S. Panchabhai
Tanmay S. Panchabhai
NDNeha S. Dangayach
Neha S. Dangayach
AKAnand Krishnan
Anand Krishnan
VKVatsal M. Kothari
Vatsal M. Kothari
DKDilip R. Karnad
Dilip R. Karnad

16 April 2014 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
DKDilip R. Karnad
Dilip R. Karnad
RBRakesh Bhadade
Rakesh Bhadade
PVPradeep K. Verma
Pradeep K. Verma
NMNivedita D. Moulick
Nivedita D. Moulick
MDMradul K. Daga
Mradul K. Daga
SIShivakumar Iyer
Shivakumar Iyer
Purpose Ulinastatin, a serine protease inhibitor, inhibits several pro-inflammatory proteases and decreases inflammatory cytokine levels and mortality in experimental sepsis. We studied the effect of ulinastatin on 28-day all-cause mortality in a double-blind trial in patients with severe sepsis in seven Indian hospitals. Methods Patients with sepsis were randomized within 48 h of onset of one or more organ failures to receive intravenous administration of ulinastatin (200,000 IU) or placebo 12 hourly for 5 days. Results Of 122 randomized subjects, 114 completed the study (55 receiving ulinastatin, 59 receiving placebo). At baseline, the mean APACHE II score was 13.4 (SD = 4.4), 48 (42 %) patients were receiving mechanical ventilation, 58 (51 %) were on vasopressors, and 35 % had multiple organ failure. In the modified intention-to-treat analysis (patients receiving six or more doses of study drugs), 28-day all-cause mortality was 7.3 % with ulinastatin (4 deaths) versus 20.3 % (12 deaths) with placebo (p = 0.045). On multivariate analysis too, treatment with ulinastatin (odds ratio 0.26, 95 % CI 0.07–0.95; p = 0.042) independently decreased 28-day all-cause mortality. However, the mortality difference did not reach statistical significance in the intention-to-treat analysis [10.2 % (6/59 deaths) with ulinastatin versus 20.6 % (13/63 deaths) in the placebo group; p = 0.11]. The ulinastatin group had lower incidence of new-onset organ failure (10 vs. 26 patients, p = 0.003), more ventilator-free days (mean ± SD 19.4 ± 10.6 days vs. 10.2 ± 12.5 days, p = 0.019), and shorter hospital stay (11.8 ± 7.1 days vs. 24.2 ± 7.2 days, p < 0.001). Conclusions In this pilot study, intravenous administration of ulinastatin reduced mortality in patients with severe sepsis in the modified intention-to-treat analysis, but not in the intention-to-treat analysis.

1 January 2021 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
ANAmit M Narkhede
Amit M Narkhede
DKDilip R Karnad
Dilip R Karnad
Narkhede AM, Karnad DR. Preeclampsia and Related Problems. Indian J Crit Care Med 2021;25(Suppl 3):S261–S266.

1 May 2021 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
VGVishal Gupta
Vishal Gupta
DKDilip R Karnad
Dilip R Karnad
Tetanus is caused by an exotoxin, tetanospasmin, produced by Clostridium tetani, an anaerobic gram-positive bacillus.Tetanospasmin prevents the release of inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the spinal cord, brainstem motor nuclei, and the brain, producing muscle rigidity and tonic spasms.Trismus (lockjaw), dysphagia, laryngeal spasms, rigidity of limbs and paraspinal muscles, and opisthotonic posture are common.Frequent severe spasms triggered by touch, pain, bright light, or sounds may produce apnea and rhabdomyolysis.Autonomic overactivity occurs in severe tetanus causing labile hypertension, tachycardia, increased secretions, sweating, and urinary retention. Dysautonomia is difficult to manage and is a common cause of mortality; magnesium sulfate infusion is often used.Antibiotics (penicillin or metronidazole) and wound care reduce toxin production and human tetanus immune globulin neutralizes the circulating toxin.Nasogastric tube placement for feeding and medications is needed.Early elective tracheostomy is performed in moderate or severe tetanus to prevent aspiration and laryngeal stridor.Benzodiazepines help reduce rigidity, spasms, and autonomic dysfunction. Large doses of diazepam (0.2–1 mg/kg/h) are administered via nasogastric tube.Neuromuscular blocking agents and mechanical ventilation are used for refractory spasms.Mortality ranges from 5% to 50%.

1 August 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
DKDilip R. Karnad
Dilip R. Karnad
GRGuy Richards
Guy Richards
GSGisele Sampaio Silva
Gisele Sampaio Silva
PAPravin Amin
Pravin Amin

1 April 2006
Verified
Journal Article
Closed access
VKVatsal M Kothari
Vatsal M Kothari
DKDilip R Karnad
Dilip R Karnad
LBLata S Bichile
Lata S Bichile